Skip to content

The clinical study of using recombinant luteinizing hormone under the GnRH antagonist protocol to improve the clinical outcome of normal ovarian response women with previous IVF/ ICSI-ET failure

The clinical study of using recombinant luteinizing hormone under the GnRH antagonist protocol to improve the clinical outcome of normal ovarian response women with previous IVF/ ICSI-ET failure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098379
Enrollment
Unknown
Registered
2025-03-06
Start date
2024-10-14
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Group A (Gn start day with rLH):None
Group B (antagonist daily addition of rLH):None

Sponsors

Renmin Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
22 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1) Normal reaction population: a. Age and AFCs 1.1 ng/mL and AMH =1 year, with indications for IVF or ICSI; 4) No high-quality embryos on day 3 of the first IVF/ICSI cycle and no pregnancy after transfer; 5) the first IVF/ICSI cycle is cancelled due to the lack of transferable embryos; 6) rLH was not used in the first COH procedure.

Exclusion criteria

Exclusion criteria: 1)Combined with other systemic serious diseases such as liver and kidney insufficiency, systemic lupus erythematosus; 2)According to researcher's evaluation, the patients might have clinical significant abnormalities in uterus or uterine appendages, including but not limited to reproductive system malformation, uterine fibroids, uterine adhesions, thin endometrium (secretory endometrium thickness =10 mm in diameter is over than 20, or the estradiol level is >=4000 pg/mL during COH process, or with the history of moderate or severe OHSS, or with a history of cycle cancellation due to OHSS risk.

Design outcomes

Primary

MeasureTime frame
The number of available embryos;

Secondary

MeasureTime frame
Number of oocyte retrieved;Fertilization rate ;Good-quality embryo rate;Clinical pregnancy rate;Cycle cancellation rate;Time to pregnancy;

Countries

China

Contacts

Public ContactQi Qianrong

Renmin Hospital of Wuhan University

qi_qianrong@126.com+86 177 2048 0509

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026